caa a22 4500 378898078 CHVBK 20180305123511.0 cr unu---uuuuu 161128e20041201xx s 000 0 eng 10.1515/CCLM.2004.257 doi (NATIONALLICENCE)gruyter-10.1515/CCLM.2004.257 Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay [Elektronische Daten] [Friedrich Schulze, Reinhard Wesemann, Edzard Schwedhelm, Karsten Sydow, Jennifer Albsmeier, John P. Cooke, Rainer H. Böger] Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase (NOS). Elevated ADMA plasma levels have been reported in connection with diseases associated with an impaired endothelial L-arginine-NO pathway and endothelial dysfunction, such as atherosclerosis, hypercholesterolemia, chronic heart failure, diabetes mellitus, and hypertension. NO production by NOS is decreased due to elevated ADMA levels. In fact, there is increasing interest in determination of ADMA levels in samples of various origins. The aim of this work was to develop a precise and easy immunoassay in contrast to the existing methods, such as HPLC, liquid chromatography-mass spectrometry (LC-MS) and gas chromatography (GC)-MS. We determined cross-reactivity in our immunoassay of 1.2% for symmetric dimethylarginine and <0.02% for L-arginine. The limit of quantitation was 0.05μmol/l. We found good correlation of the values measured when we compared our assay with LC-tandem MS (n=29; r=0.984; p<0.0001). We determined ADMA levels in human serum and plasma, mouse and rat plasma, and cell culture supernatant. For human plasma we found a mean of 0.65μmol/l in healthy subjects. In the plasma of mice and rats we found mean concentrations of 1.05 and 1.09μmol/l, respectively. ©2004 by Walter de Gruyter Berlin New York Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence dimethylarginine nationallicence endothelial dysfunction nationallicence inhibitor nationallicence NO pathway nationallicence risk factor nationallicence Schulze Friedrich Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut Wesemann Reinhard DLD Diagnostika GmbH, Hamburg, Germany aut Schwedhelm Edzard Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut Sydow Karsten Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, USA aut Albsmeier Jennifer Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut Cooke John P. Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, USA aut Böger Rainer H. Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut Clinical Chemical Laboratory Medicine Walter de Gruyter 42/12(2004-12-01), 1377-1383 1434-6621 42:12<1377 2004 42 cclm https://doi.org/10.1515/CCLM.2004.257 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/CCLM.2004.257 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schulze Friedrich Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Wesemann Reinhard DLD Diagnostika GmbH, Hamburg, Germany aut NATIONALLICENCE 700 1- Schwedhelm Edzard Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Sydow Karsten Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, USA aut NATIONALLICENCE 700 1- Albsmeier Jennifer Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Cooke John P. Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, USA aut NATIONALLICENCE 700 1- Böger Rainer H. Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 773 0- Clinical Chemical Laboratory Medicine Walter de Gruyter 42/12(2004-12-01), 1377-1383 1434-6621 42:12<1377 2004 42 cclm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter